Want to see TSE:KNE full AI Analyst Report?
KNE Stock Chart & Stats
C$0.03
<C$0.01(4.76%)
At close: 4:00 PM EST
C$0.03
<C$0.01(4.76%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.05
Previous CloseN/A
Volume199.87K
Average Volume (3M)112.95K
Market Cap
C$5.13M
Enterprise ValueC$6.98M
Total Cash (Recent Filing)C$395.06K
Total Debt (Recent Filing)C$1.92M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding205,056,560
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Anti-biofilm PlatformKane's core technology targets microbial biofilms, a persistent clinical and industrial problem. A defensible platform addressing multiple use cases (wound care, animal health, industrial) creates durable differentiation, supporting multi-year commercialization and licensing opportunities beyond short-term cycles.
Diversified Revenue ModelA three-pronged monetization approach—direct product sales, licensing/royalties, and partner collaborations—provides structural optionality. Licensing and collaborations can scale revenue with limited capex, smoothing growth and offering higher-margin, recurring streams that persist over quarters if partners execute.
Improving Cash Burn TrendReduced absolute cash burn and FCF that aligns with reported losses indicate improving operational discipline. Even while cash flow remains negative, this trend lowers near-term refinancing pressure and, if sustained, enhances runway and strategic optionality over the next several months.
Bears Say
Severe Revenue Decline And Negative Gross ProfitAn 86% TTM revenue collapse coupled with negative gross profit reflects deep demand or commercialization failures and poor pricing/production economics. Such structural top-line deterioration undermines operating leverage and makes sustainable profitability unlikely without material product, commercial, or market changes.
Negative Shareholders' EquityNegative equity restricts financial flexibility, raises refinancing and dilution risk, and can impede access to credit or favorable partner terms. This structural balance-sheet weakness constrains strategic options and increases the probability of equity raises or restructuring over the medium term.
Persistent Negative Operating Cash FlowOngoing negative OCF/FCF indicates the business consumes cash to operate and scale, requiring external funding. Even with improved burn, sustained outflows erode liquidity and raise dilution risk, limiting ability to invest in commercialization or R&D absent new capital or partner funding.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.02 and its highest was C$0.05 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$5.13M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is Aug 27, 2026 which is in 47 days.
How were Kane Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 205,056,560 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.
Technical Analysis
―
XORTX Therapeutics Inc
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---